查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1604650

節肢動物傳播的病毒傳染病檢查市場：按測試類型、最終用戶分類 - 2025-2030 年全球預測

Arthropod-borne Viral Infections Testing Market by Test Type (Cultural Tests, Immunoassays, Molecular Tests), End-user (Diagnostic Centers, Hospitals, Research Centers) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

節肢動物病毒傳染病檢查市場2023年估值為109.9億美元，預計2024年將達到121.8億美元，複合年成長率為10.88%，到2030年預計將達到226.6億美元。

節肢動物傳播的病毒傳染病檢查的範圍包括旨在檢測透過節肢動物（例如蚊子、蜱蟲和跳蚤）傳播的病毒感染的診斷程序。這些感染疾病包括茲卡病毒、登革熱、屈公病和西尼羅河病毒。對此類檢測的需求源於快速、準確診斷的需要，以促進及時的醫療干預、控制疫情並指導公共衛生措施。最終用途包括公共衛生機構、研究機構和醫療設施，以及實驗室、醫院和診斷中心的應用。市場成長受到全球旅行增加、都市化、氣候變遷以及節肢動物傳播疾病意識增強等因素的影響，導致對先進檢測方法的需求增加。 PCR 和次世代定序等分子診斷技術的進步帶來了潛在的商機。建議包括投資研發，開發具有成本效益、快速且高度準確的測試解決方案，特別是可以使偏遠和資源貧乏地區的訪問民主化的照護現場診斷。

主要市場統計
基準年[2023] 109.9億美元
預測年份 [2024] 121.8億美元
預測年份 [2030] 226.6億美元
複合年成長率（%） 10.88%

影響市場的挑戰包括監管障礙、先進測試技術的高成本以及新興市場地區基礎設施有限。此外，抗藥性病毒株的出現和盛行率的區域差異增加了複雜性。此外，缺乏熟練的專業人員來進行和解釋測試也可能會限制市場的成長。整合資料分析和人工智慧的多重測試平台和數位解決方案的創新可以開闢新的研究途徑。與政府和非政府組織合作提供資金籌措和支援可以減少進入障礙並擴大影響範圍。市場洞察表明，迫切需要共同努力對衛生專業人員和公眾進行預防措施教育。該市場本質上是動態的，並且受到節肢動物傳播性行為感染的季節性和地理波動的影響。將傳統診斷與新技術相結合的積極主動的方法對於抓住成長機會並應對這一市場格局中的挑戰至關重要。

市場動態：快速發展的節肢動物傳播病毒傳染病檢查市場的關鍵市場洞察

節肢動物傳播的傳染病檢查市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 節肢動物傳播的病毒感染增加
    • 改進節肢動物傳播病毒的診斷方法
    • 關於蟲媒病毒感染疾病的政府措施和宣傳宣傳活動
  • 市場限制因素
    • 節肢動物傳播的病毒感染疾病診斷試劑套件發生產品召回
  • 市場機會
    • 擴大基於 ELISA 的診斷測試的接受度
    • 測試方法的技術進步
  • 市場問題
    • 開發用於研發和疫苗開發的蟲媒病毒動物模型的困難

波特的五力：駕馭節肢動物傳播的病毒傳染病檢查市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點，避免潛在的挑戰，確保更強大的市場地位。

PESTLE分析：了解節肢動物病毒傳染病檢查市場的外部影響

外部宏觀環境因素在塑造節肢動物病毒傳染病檢查市場的績效動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析：了解節肢動物傳播的病毒傳染病檢查市場的競爭格局

對節肢動物傳播的病毒傳染病檢查市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣：節肢動物傳播病毒傳染病檢查市場供應商的績效評估

FPNV 定位矩陣是評估節肢動物病毒傳染病檢查市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：在節肢動物傳播的病毒傳染病檢查市場中製定成功之路

對於希望加強在全球市場的影響力的公司來說，對節肢動物傳播的病毒傳染病檢查市場進行策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1. 市場滲透率：詳細檢視當前市場環境，主要企業的廣泛資料，評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、主要產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 節肢動物傳播的病毒感染增加
      • 改善節肢動物傳播的病毒診斷
      • 關於蟲媒病毒感染的政府措施和宣傳宣傳活動
    • 抑制因素
      • 節肢動物傳播病毒感染疾病診斷試劑套件產品回收案例
    • 機會
      • 基於ELISA的檢測診斷的普及
      • 測試方法的技術進步
    • 任務
      • 開發用於研究和疫苗開發的蟲媒病毒動物模型的困難
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章節肢動物傳播的病毒傳染病檢查市場：依檢測類型

  • 介紹
  • 文化測試
  • 免疫學測試
  • 分子檢測

第7章節肢動物傳播的病毒傳染病檢查市場：依最終用戶分類

  • 介紹
  • 診斷中心
  • 醫院
  • 研究中心

第8章 美洲節肢動物病毒傳染病檢查市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太節肢動物病毒傳染病檢查市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章歐洲、中東和非洲節肢動物病毒傳染病檢查市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • Abnova Corporation
  • ACROBiosystems
  • AdvaCare Pharma
  • ARUP Laboratories
  • Bio Lab Diagnostics（I）Private Limited
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne
  • BIOGENIX INC. PVT. LTD.
  • bioMerieux SA
  • Chembio Diagnostics, Inc.
  • Clongen Laboratories, LLC
  • Coppe Laboratories
  • EIKEN CHEMICAL Co., Ltd.
  • Elabscience BIoTechnology Inc.
  • EUROIMMUN AG by PerkinElmer Inc.
  • F. Hoffmann-La Roche Ltd
  • Hologic, Inc.
  • InBios International, Inc.
  • J Mitra & Co Ltd
  • Kephera Diagnostics
  • Merck KGaA
  • Quest Diagnostics Incorporated
  • Sonora Quest Laboratories LLC
  • Thermo Fisher Scientific Inc.
Product Code: MRR-4103B31E09C0

The Arthropod-borne Viral Infections Testing Market was valued at USD 10.99 billion in 2023, expected to reach USD 12.18 billion in 2024, and is projected to grow at a CAGR of 10.88%, to USD 22.66 billion by 2030.

The scope of Arthropod-borne Viral Infections Testing encompasses diagnostic procedures aimed at detecting viral infections transmitted through arthropods such as mosquitoes, ticks, and fleas. These infections include Zika virus, dengue fever, chikungunya, West Nile virus, and others. The necessity for such testing arises from the need for rapid and accurate diagnosis to facilitate timely medical interventions, control outbreaks, and guide public health policies. Applications extend to laboratories, hospitals, and diagnostic centers, with end-use spanning public health agencies, research institutes, and healthcare facilities. Market growth is influenced by factors such as the rise in global travel, urbanization, climate change, and increasing awareness about arthropod-borne diseases, leading to higher demand for advanced testing methodologies. Technological advancement in molecular diagnostics, including PCR and next-generation sequencing, presents potential opportunities. Recommendations include investing in R&D for developing cost-effective, rapid, and high-accuracy testing solutions, especially point-of-care diagnostics that could democratize access in remote or under-resourced areas.

KEY MARKET STATISTICS
Base Year [2023] USD 10.99 billion
Estimated Year [2024] USD 12.18 billion
Forecast Year [2030] USD 22.66 billion
CAGR (%) 10.88%

Challenges impacting the market include regulatory hurdles, high costs of advanced testing technology, and limited infrastructure in developing regions. Furthermore, the emergence of drug-resistant virus strains and variable prevalence rates across different geographies add complexity. Limitations in the availability of skilled professionals to perform and interpret tests may also restrain market growth. Innovations in multiplex testing platforms and digital solutions that integrate data analytics and artificial intelligence could open new research avenues. Collaborations with governmental and non-governmental organizations for funding and support can ease entry barriers and expand reach. Market insights suggest an urgent need for concerted efforts in educating healthcare professionals and the general populace regarding preventive measures. The market is inherently dynamic, driven by seasonal and geographical variations in arthropod-borne infections. A proactive approach, combining traditional diagnostic methods with emerging technologies, will be crucial for addressing the challenges while seizing growth opportunities in this market landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Arthropod-borne Viral Infections Testing Market

The Arthropod-borne Viral Infections Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing arthropod-borne viral infections
    • Improvements in arthropod-borne viral diagnostics
    • Government initiatives and awareness campaigns regarding arboviral infections
  • Market Restraints
    • Product recall incidences of arthropod-borne viral infections diagnostic kits
  • Market Opportunities
    • Rising acceptance of ELISA-based test diagnostics
    • Technological advancements in testing methods
  • Market Challenges
    • Difficulties in developing arbovirus animal models for research study and vaccine development

Porter's Five Forces: A Strategic Tool for Navigating the Arthropod-borne Viral Infections Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Arthropod-borne Viral Infections Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Arthropod-borne Viral Infections Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Arthropod-borne Viral Infections Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Arthropod-borne Viral Infections Testing Market

A detailed market share analysis in the Arthropod-borne Viral Infections Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Arthropod-borne Viral Infections Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Arthropod-borne Viral Infections Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Arthropod-borne Viral Infections Testing Market

A strategic analysis of the Arthropod-borne Viral Infections Testing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Arthropod-borne Viral Infections Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Abnova Corporation, ACROBiosystems, AdvaCare Pharma, ARUP Laboratories, Bio Lab Diagnostics (I) Private Limited, Bio-Rad Laboratories, Inc., Bio-Techne, BIOGENIX INC. PVT. LTD., bioMerieux SA, Chembio Diagnostics, Inc., Clongen Laboratories, LLC, Coppe Laboratories, EIKEN CHEMICAL Co., Ltd., Elabscience Biotechnology Inc., EUROIMMUN AG by PerkinElmer Inc., F. Hoffmann-La Roche Ltd, Hologic, Inc., InBios International, Inc., J Mitra & Co Ltd, Kephera Diagnostics, Merck KGaA, Quest Diagnostics Incorporated, Sonora Quest Laboratories LLC, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Arthropod-borne Viral Infections Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Test Type, market is studied across Cultural Tests, Immunoassays, and Molecular Tests.
  • Based on End-user, market is studied across Diagnostic Centers, Hospitals, and Research Centers.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing arthropod-borne viral infections
      • 5.1.1.2. Improvements in arthropod-borne viral diagnostics
      • 5.1.1.3. Government initiatives and awareness campaigns regarding arboviral infections
    • 5.1.2. Restraints
      • 5.1.2.1. Product recall incidences of arthropod-borne viral infections diagnostic kits
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising acceptance of ELISA-based test diagnostics
      • 5.1.3.2. Technological advancements in testing methods
    • 5.1.4. Challenges
      • 5.1.4.1. Difficulties in developing arbovirus animal models for research study and vaccine development
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Arthropod-borne Viral Infections Testing Market, by Test Type

  • 6.1. Introduction
  • 6.2. Cultural Tests
  • 6.3. Immunoassays
  • 6.4. Molecular Tests

7. Arthropod-borne Viral Infections Testing Market, by End-user

  • 7.1. Introduction
  • 7.2. Diagnostic Centers
  • 7.3. Hospitals
  • 7.4. Research Centers

8. Americas Arthropod-borne Viral Infections Testing Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Arthropod-borne Viral Infections Testing Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Arthropod-borne Viral Infections Testing Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Abnova Corporation
  • 3. ACROBiosystems
  • 4. AdvaCare Pharma
  • 5. ARUP Laboratories
  • 6. Bio Lab Diagnostics (I) Private Limited
  • 7. Bio-Rad Laboratories, Inc.
  • 8. Bio-Techne
  • 9. BIOGENIX INC. PVT. LTD.
  • 10. bioMerieux SA
  • 11. Chembio Diagnostics, Inc.
  • 12. Clongen Laboratories, LLC
  • 13. Coppe Laboratories
  • 14. EIKEN CHEMICAL Co., Ltd.
  • 15. Elabscience Biotechnology Inc.
  • 16. EUROIMMUN AG by PerkinElmer Inc.
  • 17. F. Hoffmann-La Roche Ltd
  • 18. Hologic, Inc.
  • 19. InBios International, Inc.
  • 20. J Mitra & Co Ltd
  • 21. Kephera Diagnostics
  • 22. Merck KGaA
  • 23. Quest Diagnostics Incorporated
  • 24. Sonora Quest Laboratories LLC
  • 25. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET RESEARCH PROCESS
  • FIGURE 2. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET DYNAMICS
  • TABLE 7. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CULTURAL TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 18. ARGENTINA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. ARGENTINA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 20. BRAZIL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. BRAZIL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. CANADA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. CANADA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. MEXICO ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. MEXICO ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. AUSTRALIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. AUSTRALIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. CHINA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. CHINA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. INDIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. INDIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. INDONESIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. INDONESIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. JAPAN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. JAPAN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. MALAYSIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. MALAYSIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. PHILIPPINES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. PHILIPPINES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. SINGAPORE ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. SINGAPORE ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. SOUTH KOREA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. SOUTH KOREA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. TAIWAN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. TAIWAN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. THAILAND ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. THAILAND ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. VIETNAM ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. VIETNAM ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. DENMARK ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. DENMARK ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. EGYPT ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. EGYPT ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. FINLAND ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. FINLAND ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. FRANCE ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. FRANCE ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. GERMANY ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. GERMANY ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. ISRAEL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. ISRAEL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. ITALY ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. ITALY ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. NETHERLANDS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. NETHERLANDS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. NIGERIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. NIGERIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. NORWAY ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. NORWAY ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. POLAND ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. POLAND ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. QATAR ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. QATAR ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. RUSSIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. RUSSIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. SAUDI ARABIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SAUDI ARABIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. SPAIN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SPAIN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. SWEDEN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. SWEDEN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. SWITZERLAND ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. SWITZERLAND ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. TURKEY ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. TURKEY ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED ARAB EMIRATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED ARAB EMIRATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED KINGDOM ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED KINGDOM ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 102. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET, FPNV POSITIONING MATRIX, 2023